Estimation of binding affinities for HEPT and nevirapine analogues with HIV-1 reverse transcriptase via Monte Carlo simulations.

The interactions and energetics associated with the binding of 20 HEPT and 20 nevirapine nonnucleoside inhibitors of HIV-1 reverse transcriptase (RT) have been explored in an effort to establish simulation protocols and methods that can be used in the development of more effective anti-HIV drugs. Using crystallographic structures as starting points, all 40 inhibitors were modeled in the bound and unbound states via Monte Carlo (MC) statistical mechanics methods. Potentially useful descriptors of binding affinity were configurationally averaged for each inhibitor during the MC simulations, and correlations were sought with reported experimental activities. A viable regression equation was obtained using only four descriptors to correlate the 40 experimental activities with an r(2)() of 0.75 and cross-validated q(2)() of 0.69. The computed activities show a rmsd of 0.94 kcal/mol in comparison with experiment and an average unsigned error of 0.69 kcal/mol. The MC results reveal three physically reasonable parameters that control the binding affinities: (1) loss of hydrogen bonds with the inhibitor is unfavorable, (2) burial of hydrophobic surface area is favorable, and (3) a good geometrical fit without steric clashes is needed for the protein-inhibitor complex. It is gratifying that the corresponding descriptors are statistically the most important quantities for determining the anti-HIVRT activity for the 40 compounds. Representative examples are also given in which structural and thermodynamic information from the MC simulations is used to help understand binding differences for related compounds. A key pi-type hydrogen bond has been identified between secondary-amide nevirapine analogues and Tyr188A of HIVRT that explains their otherwise surprising activity and the ineffectiveness of nevirapine against the Y188C mutant.

[1]  R T Walker,et al.  Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. , 2010, Journal of medicinal chemistry.

[2]  William L. Jorgensen,et al.  Free Energy Changes in Solution , 2002 .

[3]  W. L. Jorgensen,et al.  Prediction of Properties from Simulations: Free Energies of Solvation in Hexadecane, Octanol, and Water , 2000 .

[4]  William L. Jorgensen,et al.  OPLS ALL-ATOM MODEL FOR AMINES : RESOLUTION OF THE AMINE HYDRATION PROBLEM , 1999 .

[5]  M L Lamb,et al.  Estimation of the binding affinities of FKBP12 inhibitors using a linear response method. , 1999, Bioorganic & medicinal chemistry.

[6]  P A Kollman,et al.  What determines the van der Waals coefficient β in the LIE (linear interaction energy) method to estimate binding free energies using molecular dynamics simulations? , 1999, Proteins.

[7]  M. Summers,et al.  Structural biology of HIV. , 1999, Journal of molecular biology.

[8]  M L Lamb,et al.  Prediction of binding affinities for TIBO inhibitors of HIV-1 reverse transcriptase using Monte Carlo simulations in a linear response method. , 1998, Journal of medicinal chemistry.

[9]  D I Stuart,et al.  Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. , 1998, Biochemistry.

[10]  M L Lamb,et al.  Computational approaches to molecular recognition. , 1997, Current opinion in chemical biology.

[11]  Heather A. Carlson,et al.  Free energies of solvation in chloroform and water from a linear response approach , 1997 .

[12]  W. L. Jorgensen,et al.  Binding affinities for sulfonamide inhibitors with human thrombin using Monte Carlo simulations with a linear response method. , 1997, Journal of medicinal chemistry.

[13]  D I Stuart,et al.  Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Åqvist,et al.  Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities. , 1997, Journal of medicinal chemistry.

[15]  A. D. Clark,et al.  Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. , 1996, Journal of molecular biology.

[16]  Gerhard Klebe,et al.  What Can We Learn from Molecular Recognition in Protein–Ligand Complexes for the Design of New Drugs? , 1996 .

[17]  W. L. Jorgensen,et al.  Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids , 1996 .

[18]  Elizabeth Wilson,et al.  AIDS CONFERENCE HIGHLIGHTS HOPE OF DRUG COCKTAILS, CHEMOKINE RESEARCH , 1996 .

[19]  B. Honig,et al.  New Model for Calculation of Solvation Free Energies: Correction of Self-Consistent Reaction Field Continuum Dielectric Theory for Short-Range Hydrogen-Bonding Effects , 1996 .

[20]  R. Ornstein,et al.  Binding free energy calculations for P450cam-substrate complexes. , 1996, Protein engineering.

[21]  M. Eigen On the nature of virus quasispecies. , 1996, Trends in microbiology.

[22]  Richard T. Walker,et al.  Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. , 1996, Journal of medicinal chemistry.

[23]  A. Perelson,et al.  HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.

[24]  P. Kollman,et al.  Investigating the Anomalous Solvation Free Energies of Amines with a Polarizable Potential , 1996 .

[25]  T. Hansson,et al.  Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. , 1995, Protein engineering.

[26]  D. Stuart,et al.  The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. , 1995, Structure.

[27]  Ronald M. Levy,et al.  SOLVATION FREE ENERGIES OF SMALL AMIDES AND AMINES FROM MOLECULAR DYNAMICS/FREE ENERGY PERTURBATION SIMULATIONS USING PAIRWISE ADDITIVE AND MANY-BODY POLARIZABLE POTENTIALS , 1995 .

[28]  P. Boyer,et al.  Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase. , 1995, Virology.

[29]  Peter A. Kollman,et al.  Solvation Free Energies of Amides and Amines: Disagreement between Free Energy Calculations and Experiment , 1995 .

[30]  W. L. Jorgensen,et al.  AN EXTENDED LINEAR RESPONSE METHOD FOR DETERMINING FREE ENERGIES OF HYDRATION , 1995 .

[31]  A. D. Clark,et al.  Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution , 1995 .

[32]  Yvonne Jones,et al.  High resolution structures of HIV-1 RT from four RT–inhibitor complexes , 1995, Nature Structural Biology.

[33]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[34]  E. De Clercq,et al.  Human immunodeficiency virus 1 (HIV-1)-specific reverse transcriptase (RT) inhibitors may suppress the replication of specific drug-resistant (E138K)RT HIV-1 mutants or select for highly resistant (Y181C-->C181I)RT HIV-1 mutants. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Dunitz The entropic cost of bound water in crystals and biomolecules. , 1994, Science.

[36]  T. Steitz,et al.  Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S Shigeta,et al.  Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro , 1994, Antimicrobial Agents and Chemotherapy.

[38]  J. Aqvist,et al.  A new method for predicting binding affinity in computer-aided drug design. , 1994, Protein engineering.

[39]  E. Clercq HIV resistance to reverse transcriptase inhibitors , 1994 .

[40]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[41]  R T Walker,et al.  Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. , 1992, Journal of medicinal chemistry.

[42]  R T Walker,et al.  Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. , 1992, Journal of medicinal chemistry.

[43]  J. Proudfoot,et al.  Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. , 1991, Journal of medicinal chemistry.

[44]  H. Mitsuya,et al.  Molecular targets for AIDS therapy. , 1990, Science.

[45]  W. L. Jorgensen Free energy calculations: a breakthrough for modeling organic chemistry in solution , 1989 .

[46]  L. Loeb,et al.  Fidelity of HIV-1 reverse transcriptase. , 1988, Science.

[47]  K Bebenek,et al.  The accuracy of reverse transcriptase from HIV-1. , 1988, Science.

[48]  W. L. Jorgensen,et al.  Monte Carlo simulation of differences in free energies of hydration , 1985 .

[49]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[50]  R. Wolfenden,et al.  Interaction of the peptide bond with solvent water: a vapor phase analysis. , 1978, Biochemistry.

[51]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[52]  Johan Åqvist,et al.  Ligand binding affinity prediction by linear interaction energy methods , 1998, J. Comput. Aided Mol. Des..

[53]  A. Skalka,et al.  The retroviral enzymes. , 1994, Annual review of biochemistry.

[54]  S Shigeta,et al.  A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT). , 1991, Journal of medicinal chemistry.

[55]  J Sninsky,et al.  HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. , 1989, Journal of acquired immune deficiency syndromes.